Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | -4.56% | +3.72% | -23.12% |
24/04 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
08/04 | Gain Therapeutics Names Gene Mack as CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.12% | 45.31M | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+48.60% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- Gain Therapeutics : BTIG Research Initiates Coverage on Gain Therapeutics With Buy Rating, $30 Price Target